This article analyzes the historical evolution of ADHD and its close relationship with the use of psychostimulants, showing how diagnostic changes, clinical evidence, and social pressures have shaped their contemporary understanding. Although stimulants reduce symptoms and risks associated with ADHD, their neurobiological basis remains uncertain, and diagnostic expansion has led to overdiagnosis and medicalization. Non-medical, especially in educational and work context, highlights a central bio…
Read moreThis article analyzes the historical evolution of ADHD and its close relationship with the use of psychostimulants, showing how diagnostic changes, clinical evidence, and social pressures have shaped their contemporary understanding. Although stimulants reduce symptoms and risks associated with ADHD, their neurobiological basis remains uncertain, and diagnostic expansion has led to overdiagnosis and medicalization. Non-medical, especially in educational and work context, highlights a central bioethical dilemma: the growing blurring between treatment and performance optimization. Epistemic critiques of clinical trials, the influence of the pharmaceutical industry, the identity effects of diagnosis, and the tensions between autonomy, justice, and care are examined. The article proposes strengthening institutional ethics that limit commercial interests, ensure transparency in diagnostic construction, and promote a broader understanding of attention disorders, integrating biological, social, and cultural dimensions.